< Back to situations

This situation has concluded

It was preserved as a record on September 4; the timeline below shows how it unfolded, with sources. Get the briefing to follow the top situations still developing: three emails a week, sourced and in order.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 23 sources · 7 days · First seen about 2 months ago · Last updated about 2 months ago

US pharma companies raise 2026 outlooks

Overview

In late July, Bristol Myers Squibb reported second‑quarter results that showed a 6 % year‑over‑year revenue increase and lifted its full‑year 2026 revenue guidance to $49‑$50 billion, with earnings expectations raised to $6.75‑$7.00 per share. The company highlighted strong growth in its anticoagulant Eliquis and solid performance from newer products such as Camzyos, Reblozyl, Breyanzi and the sub‑cutaneous version of Opdivo.

A week later, Pfizer announced an upward revision of its median 2026 sales outlook to $60.5‑$62.5 billion after better‑than‑expected demand for Eliquis and the heart‑disease drug Vyndaqel in the second quarter. While reporting modest revenue growth, Pfizer disclosed a $4.3 billion goodwill impairment and outlined an extension of its cost‑cutting program through 2029, targeting additional savings via automation, AI tools and staff reductions.

Both firms’ guidance upgrades reflect a broader trend among major U.S. pharmaceutical companies of boosting 2026 forecasts amid strong demand for anticoagulants and other high‑growth therapies.

Entities

Eliquis · Huvepharma · Pierre Boulud · Euroapi · bioMérieux SA

Timeline

about 2 months ago

[BUSINESS] 3 sources
Pfizer lifts 2026 sales forecast to up to $62.5 billion
Pfizer raised its 2026 sales outlook to $60.5‑62.5 bn after a strong Q2, reporting $15 bn revenue, adjusted EPS $0.77 and extending its $7 bn cost‑cut plan.
about 2 months ago

[BUSINESS] 20 sources
Bristol Myers Squibb raises 2026 revenue and profit outlook
Bristol Myers Squibb posted Q2 revenue of $12.97 bn, raised 2026 revenue guidance to $49‑$50 bn, and lifted Eliquis sales forecast to 20‑25 % growth after a 22 % sales jump.

Sources

abcbourse.com · backlinksseo.in · brunobertez.com · iatronet.gr · jkadworld.com · kfgo.com · lyoncapitale.fr · mommygearest.com · otravel.com · paparazzi.com.ar · repertoiremag.com · sbctv.gr · seekingalpha.com · siliconsemiconductor.net · srnnews.com · stocknews.com · teleborsa.it · thebusinesstimes.co.uk · webdisclosure.com · wsau.com · wtvbam.com · wvfm1065.com · wxerfm.com